AstraZeneca PLC ZEG.DE · Stock Open AstraZeneca PLC in new tab
AstraZeneca PLC Analysis (ZEG.DE)
Is AstraZeneca PLC a good investment? AstraZeneca PLC (ZEG.DE) is currently trading at 160.70 EUR.
In terms of valuation, the stock trades at a P/E ratio of 28.34. This valuation is generally in line with the broader market.
For income investors, AstraZeneca PLC pays a dividend yield of 1.69%. With a payout ratio of 48%, the dividend appears sustainable.
Investor FAQ
Does AstraZeneca PLC pay a dividend?
Yes, it pays an annual dividend of 2.72 EUR (1.69% yield).
What asset class is AstraZeneca PLC?
AstraZeneca PLC is classified as a Stock. You can compare it against 17 other assets in the "Related Symbols" list on this page.
Company Profile
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Crestor, Andexxa, Onglyza, Symlin, XIGDUO XR, Atacand, Atacand HCT, Atacand Plus, Farxiga/Forxiga, Plendil, Modip, Splendil, Munobal, Flodil, Tenormin, Tenormine, Prenormine, Atenol, Zestril, Brilinta/Brilique, Komboglyze, Qtern, Wainua, Byetta, Lokelma, Seloken ZOK, Toprol-XL, Betaloc ZOK, XIGDUO, Accolate, Accoleit, Vanticon, Bricanyl Respules, Eklira Genuair/Tudorza/Bretaris, Pulmicort Turbuhaler, Symbicort Turbuhaler, Airsupra, Bricanyl Turbuhaler, Fasenra, Rhinocort, Tezspire, Bevespi Aerosphere, Daliresp/Daxas, Oxis Turbuhaler, Saphnelo, Breztri Aerosphere, Duaklir Genuair, Pulmicort Respules, and Symbicort pMDI. It also provides Beyfortus, Kavigale, Evusheld, Fluenz/FluMist, Synagis, Kanuma, Ultomiris, Koselugo, Voydeya, Soliris, Strensiq, Nexium, and other medicines. The company offers its products for ocology, cardiovascular, renal and metabolism, respiratory & immunology, vaccines and immune, and therapies rare diseases. It serves primary and specialty care physicians through distributors and local representative offices in the United Kingdom, the Americas, rest of Europe, Asia, Africa, and Australasia. It has a strategic agreement with Tempus and Pathos to develop the largest multimodal foundation model in oncology; CSPC Pharmaceutical Group Limited to advance the discovery and development of novel oral candidates, with the potential to treat diseases across multiple indications; and Nucs AI Inc. to develop AI-driven Response Prediction for Therapeutic Radioconjugates. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
| Year | Total Dividends |
|---|---|
| ▸2027 |
0.93 EUR
|
| Aug. 6, 2027 (estimated) | 0.9271 |
| ▸2026 |
0.93 EUR
|
| Aug. 6, 2026 | 0.9271 |
| Name | Payment Date | Status | Amount |
|---|---|---|---|
| AstraZeneca PLC | Aug 06, 2026 | Paid | 0.927129 EUR |
| Split Date | Split Ratio to 1 |
|---|---|
| July 27, 2015 | 2:1 |
Community Discussion